86 related articles for article (PubMed ID: 20049769)
1. Robust non-linear mixed modelling of longitudinal PSA levels after prostate cancer treatment.
Subtil F; Rabilloud M
Stat Med; 2010 Feb; 29(5):573-87. PubMed ID: 20049769
[TBL] [Abstract][Full Text] [Related]
2. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
3. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.
Blana A; Walter B; Rogenhofer S; Wieland WF
Urology; 2004 Feb; 63(2):297-300. PubMed ID: 14972475
[TBL] [Abstract][Full Text] [Related]
4. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
Pauler DK; Finkelstein DM
Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
[TBL] [Abstract][Full Text] [Related]
5. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
6. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
7. High-intensity focused ultrasound therapy for clinically localized prostate cancer.
Lee HM; Hong JH; Choi HY
Prostate Cancer Prostatic Dis; 2006; 9(4):439-43. PubMed ID: 16847468
[TBL] [Abstract][Full Text] [Related]
8. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?
Uchida T; Illing RO; Cathcart PJ; Emberton M
BJU Int; 2006 Sep; 98(3):537-9. PubMed ID: 16925749
[TBL] [Abstract][Full Text] [Related]
9. Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy.
Hayashi M; Shinmei S; Asano K
Int J Urol; 2007 Nov; 14(11):1048-50. PubMed ID: 17956536
[TBL] [Abstract][Full Text] [Related]
10. [Transrectal high-intensity focused ultrasound with the Sonablate 500 for the treatment of prostate cancer].
Lu J; Chen ZY; Wang W; Zhang YF; Qiu XF; Zhang LC; Hu WL; Xu WF; Ye ZQ
Zhonghua Nan Ke Xue; 2007 Nov; 13(11):1005-8. PubMed ID: 18077913
[TBL] [Abstract][Full Text] [Related]
11. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
Gelet A; Chapelon JY; Bouvier R; Pangaud C; Lasne Y
J Urol; 1999 Jan; 161(1):156-62. PubMed ID: 10037389
[TBL] [Abstract][Full Text] [Related]
12. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
13. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
Bellera CA; Hanley JA; Joseph L; Albertsen PC
Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
[TBL] [Abstract][Full Text] [Related]
14. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10ng/ml].
Poissonnier L; Gelet A; Chapelon JY; Bouvier R; Rouviere O; Pangaud C; Lyonnet D; Dubernard JM
Prog Urol; 2003 Feb; 13(1):60-72. PubMed ID: 12703356
[TBL] [Abstract][Full Text] [Related]
15. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
Wirth MP; Pilarsky C
Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
[TBL] [Abstract][Full Text] [Related]
16. High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results.
Maestroni U; Ziveri M; Azzolini N; Dinale F; Ziglioli F; Campaniello G; Frattini A; Ferretti S
Acta Biomed; 2008 Dec; 79(3):211-6. PubMed ID: 19260381
[TBL] [Abstract][Full Text] [Related]
17. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study.
Uchida T; Baba S; Irie A; Soh S; Masumori N; Tsukamoto T; Nakatsu H; Fujimoto H; Kakizoe T; Ueda T; Ichikawa T; Ohta N; Kitamura T; Sumitomo M; Hayakawa M; Aoyagi T; Tachibana M; Ikeda R; Suzuki K; Tsuru N; Suzuki K; Ozono S; Fujimoto K; Hirao Y; Monden K; Nasu Y; Kumon H; Nishi K; Ueda S; Koga H; Naitoh S
Hinyokika Kiyo; 2005 Oct; 51(10):651-8. PubMed ID: 16285617
[TBL] [Abstract][Full Text] [Related]
18. Combining longitudinal studies of PSA.
Inoue LY; Etzioni R; Slate EH; Morrell C; Penson DF
Biostatistics; 2004 Jul; 5(3):483-500. PubMed ID: 15208207
[TBL] [Abstract][Full Text] [Related]
19. Treatment of localized prostate cancer using high-intensity focused ultrasound.
Uchida T; Ohkusa H; Nagata Y; Hyodo T; Satoh T; Irie A
BJU Int; 2006 Jan; 97(1):56-61. PubMed ID: 16336329
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of prostatic cancer with high intensity focused ultrasound (HIFU) using Ablatherm device].
Aliaev IuG; Krupinov GE; Bezrukov EA; Grigorian VA; Amosov AV; Chalyĭ ME; Kobzev DN; Bruk IuF; Shestiperov PA
Urologiia; 2007; (6):39-44. PubMed ID: 18649659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
